The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study
Open accessAbstract
BACKGROUND: The seed powder of the leguminous plant, Mucuna pruriens has long been used in traditional Ayurvedic Indian medicine for diseases including parkinsonism. We have assessed the clinical effects and levodopa (L-dopa) pharmacokinetics following two different doses of mucuna preparation and compared them with standard L-dopa/carbidopa (LD/CD). METHODS: Eight Parkinson's disease patients with a short duration L-dopa response and on period dyskinesias completed a randomised, controlled, double blind crossover trial. Patients were challenged with single doses of 200/50 mg LD/CD, and 15 and 30 g of mucuna preparation in randomised order at weekly intervals. L-dopa pharmacokinetics were determined, and Unified Parkinson's Disease Rating Scale and tapping speed were obtained at baseline and repeatedly during the 4 h following drug ingestion. Dyskinesias were assessed using modified AIMS and Goetz scales. RESULTS: Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations. Mean on time was 21.9% (37 min) longer with 30 g mucuna than with LD/CD (p = 0.021); peak L-dopa plasma concentrations were 110% higher and the area under the plasma concentration v time curve (area under curve) was 165.3% larger (p = 0.012). No significant differences in dyskinesias or tolerability occurred. CONCLUSIONS: The rapid onset of action and longer on time without concomitant increase in dyskinesias on mucuna seed powder formulation suggest that this natural source of L-dopa might possess advantages over conventional L-dopa preparations in the long term management of PD. Assessment of long term efficacy and tolerability in a randomised, controlled study is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
The relevance of the Lewy Body to the pathogenesis of idiopathic Parkinson's disease
Lees, A. J. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302969 · Cited by 491
Goetz, C. G., Stebbins, G. T., Shale, H. M., Lang, A. E., Chernik, D. A., Chmura, T. A., Ahlskog, J. E., & Dorflinger, E. E. (1994) · Movement Disorders · doi:10.1002/mds.870090403 · Cited by 276
FAHN, S. (1974) · Neurology · doi:10.1212/wnl.24.5.431 · Cited by 230
Association of l-DOPA with recovery following Ayurveda medication in Parkinson’s disease
Nagashayana, N., Sankarankutty, P., Nampoothiri, M. R. V., Mohan, P. K., & Mohanakumar, K. P. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00329-4 · Cited by 175
Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba.
Guggenheim, M. (1913) · Hoppe-Seyler´s Zeitschrift für physiologische Chemie · doi:10.1515/bchm2.1913.88.4.276 · Cited by 149
Paralysis agitans and levodopa in “Ayurveda”: Ancient Indian medical treatise
Manyam, B. V. (1990) · Movement Disorders · doi:10.1002/mds.870050112 · Cited by 145
Kaakkola, S., Teräväinen, H., Ahtila, S., Rita, H., & Gordin, A. (1994) · Neurology · doi:10.1212/wnl.44.1.77 · Cited by 125
Giovannoni, G., van Schalkwyk, J., Fritz, V. U., & Lees, A. J. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.5.624 · Cited by 111
Rabey, J. M., Vered, Y., Shabtai, H., Graff, E., & Korczyn, A. D. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.8.725 · Cited by 99
Apaydın, H., Ertan, S., & �zekmek�i, S. (2000) · Movement Disorders · Cited by 90
Low-dose olanzapine for levodopa induced dyskinesias
Manson, A. J., Schrag, A. E., & Lees, A. J. (2000) · Neurology · doi:10.1212/wnl.55.6.795 · Cited by 68
Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations
Kurth, M., Tetrad, J. W., Irwin, I., Lyness, W. H., & Langston, J. W. (1993) · Neurology · doi:10.1212/wnl.43.5.1036 · Cited by 68
Domperidone and levodopa in Parkinson's disease.
Shindler, J. S., Finnerty, G. T., Towlson, K. E., et al. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02571.x · Cited by 62
Treatment of Parkinson's disease with the cowhage plant-Mucuna pruriens Bak.
Vaidya, A. B., Rajagopalan, T. G., Mankodi, N. A., Antarkar, D. S., Tathed, P. S., Purohit, A. V., & Wadia, N. H. (1978) · PubMed · Cited by 58
Merello, M., Pikielny, R., Cammarota, Á., & Leiguarda, R. C. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199704000-00008 · Cited by 46
May, P. R. A., Lee, M. A., & Bacon, R. C. (1983) · Clinical Neuropharmacology · doi:10.1097/00002826-198300061-00006 · Cited by 45
Worsening of levodopa-induced dyskinesias by motor and mental tasks
Durif, F., Vidailhet, M., Debilly, B., & Agid, Y. (1999) · Movement Disorders · Cited by 43
Modification of Levodopa Effect by Systemic Decarboxylase Inhibition
Mars, H. (1973) · Archives of Neurology · doi:10.1001/archneur.1973.00490200039004 · Cited by 41
DIHYDROXYPHENYLALANINE, A CONSTITUENT OF THE VELVET BEAN
Miller, E. R. (1920) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86253-6 · Cited by 40
Plasma Concentration of Levodopa in Patients with Parkinson’s Disease
Rinne, U. K., Sonninen, V. H., & Siirtola, T. (2008) · European Neurology · doi:10.1159/000114285 · Cited by 39
Effect of Supplemental Carbidopa on Bioavailability of l-Dopa
Cedarbaum, J. M., Kutt, H., Dhar, A. K., Watkins, S., & MCDOWELL, F. H. (1986) · Clinical Neuropharmacology · doi:10.1097/00002826-198604000-00006 · Cited by 33
Decarboxylation of orally administered l-dopa in the human digestive tract
Bergmark, J., Carlsson, A., Granérus, A., JAGENBURG, R., Magnusson, T., & Svanborg, A. (1972) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00501249 · Cited by 23
Nutt, J. G. (1995) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1995.tb01946.x · Cited by 21
Pareja, F. B., Martínez‐Martín, P., Muradás, V., & de Yébenes, J. G. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1985.tb00908.x · Cited by 14
Yazawa, I., Terao, Y., Sai, I. V., Hashimoto, K., & Sakuta, M. (1994) · PubMed · Cited by 8
Cited by
Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery
Lee, V. M.-Y., & Trojanowski, J. Q. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.026 · Cited by 479
Peterson, C. T. (2020) · Journal of Evidence-Based Integrative Medicine · doi:10.1177/2515690x20957225 · Cited by 160
Metadata
- Authors
- Katzenschlager, R.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2004-12-01
- Volume
- 75
- Issue
- 12
- Pages
- 1672-1677
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2156635671
- Cited by
- 318
- References
- 31
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.